Macrogen Europe is seeking to access the Swiss market from its office in the Basel Area providing Sanger sequencing, next generation sequencing (NGS) and bioinformatics services to scientists. To this end, the South Korean company with European headquarters in Amsterdam has chosen the Novartis Campus site of the Switzerland Innovation Park Basel Area.

This year, Macrogen Europe was named Top Sanger Sequencing Services Company 2023 by the North American biotech magazine “Life Sciences Review”. Since 2008, Macrogen Europe has been focused on supporting genomics researchers in Europe and Africa. With its Sanger and Next Generation sequencing laboratories, the company claims to be able to ensure fast turnaround times.

“Our powerful sequencing services are designed to take up as little research time as possible, because project delays are simply not an option for us”, comments Bongcho Kim, CEO of Macrogen Europe, before adding: “Our plan for Basel is to expand within Switzerland with our in-house laboratory sequencing”.

Existing life sciences cluster as reason for settlement

Initially, the company intends to move closer to its customers with two employees in Basel. Thereafter, the plan is to gradually increase the local workforce to between five and ten staff members at a physical lab in Switzerland. As the main reasons for choosing the Basel Area, Macrogen cites the appeal of the existing life sciences cluster and central location on the border with Germany and France.

The Swiss Business Hub Korea, which represents the official Swiss consultancy, promotion and platform organization for export and investment promotion, Switzerland Global Enterprise, in Seoul, initiated the first contact with the investment and innovation promotion agency Basel Area Business & Innovation.